DIRS.INFO The most relevant business & tech news

☆ What happened to 23andMe?
▼ + stars: | 2024-09-20 | by ( Allison Morrow | ) edition.cnn.com time to read: +5 min

Takes the company public. 23andMe went public in 2021, jumping on the SPAC trend of the era, when a bunch of companies went public via “special purpose acquisition companies” — essentially shell-company mergers that let firms go public in a hurry when investor appetite is strong. 23andMe co-founder and CEO Anne Wojcicki, pictured in 2020. Side note: I did my own 23andMe test, in 2019, motivated by a millennial compulsion to spend money on any product that promises to alleviate and/or deepen my corporeal angst. 23andMe has tried to convert one-time buyers into subscribers with the promise of continued feedback and personalized wellness plans.

Persons: CNN Business ’, it’d, Anne Wojcicki, ”, It’s, Susan Wojcicki, 23andMe, Emma McIntyre, Oprah’s, there’s …, Wojcicki, “ Organizations: CNN Business, New York CNN, Yale, Google, Wall Street, Wall Street Journal Locations: New York, Bay

☆ Feel like GLP-1 weight loss drugs affect your mood? Experts weigh in
▼ + stars: | 2024-09-19 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +9 min

Although originally prescribed to treat type 2 diabetes (Ozempic and Mounjaro), semaglutide and tirzepatide are becoming more and more popular for weight loss. If you are noticing an effect on your mood while using a GLP-1 medication, here’s what might be at play. Antidepressant effectsFor some, using a GLP-1 medication might relieve some anxiety or depression symptoms, Arillotta said. Blood sugarIf you feel like your mood takes a drop while you’re on GLP-1 medications, what and how much you’re eating or drinking might be to blame. “Extremes in blood sugar can impact mood,” said Tara Schmidt, lead dietitian at the Mayo Clinic Diet, an online weight loss program.

Persons: ideation, Thomas Wadden, Davide Arillotta, Arillotta, “, Peter Ueda, Amira Guirguis, ”, Tara Schmidt, ” Schmidt, Guirguis, Giuseppe Floresta, Fabrizio Schifano, ” Guirguis, aren’t, you’ve, Schmidt, “ I’m, Ueda Organizations: Lifeline, CNN, US Food and Drug Administration, Perelman School of Medicine, University of Pennsylvania, FDA, neurosciences, University of Florence, Karolinska Institutet, Diabetes, Swansea University, Mayo Clinic Diet, University of Catania, University of Hertfordshire, American Psychological Association, “ Locations: Italy, Stockholm, Sweden, GLP, Wales, United Kingdom

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Kate Moss' half-sister Lottie Moss, 26, says she ended up in the hospital after using Ozempic that she got from a friend
▼ + stars: | 2024-09-13 | by ( Amanda Goh | ) www.businessinsider.com time to read: +4 min

Read previewLottie Moss, 26, is speaking out about the dangers of taking Ozempic. During an episode of her "Dream On" podcast, the model — who is Kate Moss' half-sister — said she ended up in a hospital after taking the drug. Moss said she went to the hospital after a particularly bad day when she couldn't keep any liquids or food down. Reflecting on her use of Ozempic, Moss called it "the worst decision I ever made." AdvertisementLast year in Austria, several people were brought to the hospital with life-threatening seizures after taking counterfeit versions of the drug.

Persons: —, Lottie Moss, Kate Moss, I'm, Moss, didn't, Eric Kastango, Ozempic, semaglutide Organizations: Service, Business, Novo Nordisk, FDA, Austrian Federal Office, Safety, Health Care Locations: Austria

☆ Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
▼ + stars: | 2024-09-12 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +5 min

Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform. Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website.

Persons: Wegovy, Noom, Geoff Cook, Cook, Dr, Adonis Saremi, They'll Organizations: CNBC, U.S . Food, Drug Administration, FDA Locations: U.S, United States

☆ Harris-Trump debate highlights and Hurricane Francine approaches Louisiana: Morning Rundown
▼ + stars: | 2024-09-11 | by ( Elizabeth Robinson | Elizabeth Robinson Is A Newsletter Editor For Nbc News | Based In Los Angeles. | ) www.nbcnews.com time to read: +7 min

And while Trump tried to tie Harris to President Joe Biden, he learned that she is a much tougher rival. While Trump tried to re-create the conditions of June’s fateful debate stage matchup, Harris reminded him, “You’re not running against Joe Biden. Harris tried to get under Trump’s skin, baiting him into a defensive posture that prevented him from attacking her weaknesses. And when Trump scolded Harris’ attempt to interrupt him, some allies lamented that he lost control at a key moment. Three Republican sources told NBC News after the debate that Trump came off as “angry” in that moment.

Persons: Kamala Harris, Donald Trump’s, Francine churns, Harris, Donald Trump, Trump, Joe Biden, “ You’re, You’re, ” Harris, Harris ’, ” Trump, Louisiana Hurricane Francine, Joe Wilson of, ”, Republican Kelly Ayotte, Joyce Craig, Mauricio Pochettino, Dave Grohl, Hill, Jesse Dittmar, James Earl Jones ’, Darth Vader, Jones, Char Adams, — Joy Y, Wang, Dermatologists, Elizabeth Robinson Organizations: Trump, Republican, NBC News, Federal, Labor Statistics, Louisiana Hurricane, Public, Novo Nordisk, Foo Fighters, Police, Miami Dolphins, NBC Locations: Louisiana, Ohio, New Orleans, Mississippi, Novo, semaglutide, Wegovy, Joe Wilson of South Carolina, Washington, ” New Hampshire, Ukraine, Russia

The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs. “It’s roughly double the weight loss rate seen with current GLP-1 agonists and approaching procedural or surgical-level outcomes,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina. McGowan said that while the weight loss was significant, he still has concerns about how fast people lost weight. “While losing weight is seemingly the end goal, how that weight is lost matters,” he said. Spratt said she would like to know how much of the weight loss came from fat compared with muscle.

Persons: “, ”, Christopher McGowan, ” Dr, Susan Spratt, Spratt, haven’t, Martin Lange, Lange, McGowan, ” McGowan Organizations: Novo Nordisk, European Association for, Diabetes, Population Health Management, Duke Health Locations: Novo, Spain, North Carolina, semaglutide, Wegovy, It’s

The findings bring the phenomenon — and the controversy — of the latest new and powerful weight loss drugs to the youngest age group yet. The new trial looked at liraglutide, the active ingredient used in two of Novo Nordisk’s older GLP-1 drugs: Saxenda, a weight loss drug, and Victoza, a diabetes drug. So instead of looking at overall weight loss like in adult studies, they decided to focus more on BMI, which takes into account both weight and height. A spokesperson for Novo Nordisk said that it has submitted an application to the Food and Drug Administration to expand the approval of liraglutide for weight loss in children ages 6 to 11. Is 6 too young for a weight loss drug?

Persons: Roy Kim, “, ” Kim, Claudia Fox, Fox, Eli Lilly, ”, liraglutide, ” Fox, Sarah Armstrong, ” Armstrong, comorbidities, it’s, ” Wegovy, Zepbound, Shauna Levy, ” Levy Organizations: New England, of Medicine, Novo Nordisk, Cleveland Clinic, Centers for Disease Control, University of Minnesota, BMI, Food and Drug Administration, American Academy of Pediatrics, Duke University, Tulane Bariatric Center Locations: liraglutide, Ozempic, Ohio, U.S, New Orleans

☆ A man rapidly lost weight on a popular weight-loss drug. After 6 months, he was hospitalized with heart problems and confusion.
▼ + stars: | 2024-08-07 | by ( ) www.businessinsider.com time to read: +4 min

Read previewSix months after he started taking a weight-loss drug, a 62-year-old man was hospitalized with heart palpitations, tremors, confusion, fever, and sweating. The man, from Colorado, had been prescribed the drug tirzepatide (the active ingredient in Mounjaro and Zepbound) to lose weight. Over time, the patient decreased his insulin dose as he lost weight, but didn't change his thyroid medication. This highlights the potential risks of losing weight too quickly, and the need for medical supervision while using the drugs, they said. AdvertisementOzempic and Wegovy, brand names for semaglutide showed weight loss of about 15% over a similar time period.

Persons: —, Barbara Davis, they've Organizations: Service, Business, Barbara, Barbara Davis Center, Diabetes, University of Colorado, FDA Locations: Colorado

☆ Nearly half of online pharmacies selling weight loss drugs are operating illegally, study finds
▼ + stars: | 2024-08-02 | by ( Liz Szabo | Liz Szabo Is An Independent Health | Science Journalist. Her Work Has Won Multiple National Awards. One Of Her Investigations Led To A New State Law In Virginia. | ) www.nbcnews.com time to read: +8 min

Consumers who try to buy popular weight loss drugs online without a prescription risk being scammed or receiving unsafe products, a new study shows. Shortages of the popular weight loss medication, which belongs to a class of drugs called GLP-1s, have led to “a black market of illegal knockoffs,” said Dr. Christopher McGowan, the founder, medical director and research director of True You Weight Loss, a weight loss clinic in Cary, North Carolina. Medicare doesn’t cover the drugs when prescribed for weight loss, and many state Medicaid plans heavily restrict coverage. Online scamsSome websites purporting to be online pharmacies take consumers’ money but never deliver the medications, according to the study. Consumers won’t get that sort of care if they buy drugs online without seeing a health care provider.

Persons: ”, Tim Mackey, Christopher McGowan, McGowan, semaglutide, won’t, Mackey, ” McGowan, “, Shabbir Safdar, Scott Brunner, Safdar, Brunner, Consumers won’t, it’s Organizations: Nordisk’s, University of California, Global Health, Data Institute, University of Pecs, FDA, Manufacturers can’t, Medicare, JAMA, Food and Drug Administration, semaglutide, Novo Nordisk, telltale, Partnership, Safe Medicines, Alliance, Pharmacy, Consumers Locations: San Diego, Hungary, Cary , North Carolina, U.S

☆ Weight-loss drugs could stave off dementia, small study finds
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.

Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo

☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Popular weight-loss and diabetes medications show promise for curbing smoking, study suggests
▼ + stars: | 2024-07-29 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

But experts emphasize that much more research is needed before using the medications off-label for smoking cessation. In a study published Monday in the journal Annals of Internal Medicine, researchers tracked the medical records of more than 200,000 people who started medications to treat type 2 diabetes, including nearly 6,000 people using semaglutide medications such as Ozempic. Over the course of a year, people who started using semaglutide were significantly less likely to have medical encounters for tobacco use disorders, prescriptions for medications for smoking cessation or counseling for smoking cessation than those who started other diabetes medications such as insulin and metformin. “A signal like this one cannot be ignored, particularly because of how consequential it could be if, in fact, we can have now a new medication for treating smoking cessation,” she said. But fewer than 1 in 10 adult cigarette smokers succeed in quitting each year, according to the new study, and options for smoking cessation treatment haven’t changed much in decades.

Persons: Disha, ”, Nora Volkow, ” Volkow, Dr, Sanjay Gupta, Volkow Organizations: CNN, Internal Medicine, Endeavor Health, National Institute on Drug, Get CNN, CNN Health, US Centers for Disease Control, American Cancer Society Locations: Chicago, United States

☆ The FDA says patients may be overdosing on imitation semaglutide weight-loss drugs because the directions are unclear
▼ + stars: | 2024-07-27 | by ( Lauren Edmonds | ) www.businessinsider.com time to read: +1 min

The FDA said people may be overdosing on knock-off semaglutide weight-loss drugs. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email. AdvertisementThe US Food and Drug Administration says some people have been hospitalized with symptoms that may be related to overdoses from injectable weight-loss drugs. This story is available exclusively to Business Insider subscribers.

Persons: — Organizations: FDA, Service, Food and Drug Administration, Business

☆ Novo Nordisk's Wegovy wins EU backing for reducing heart risks
▼ + stars: | 2024-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults. "The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events." Novo Nordisk said it expects to implement the label update within a month. The company's CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential."

Persons: Wegovy, —, Martin Holst Lange, Roche, Thomas Schinecker Organizations: Novo Nordisk, Novo, European Medical Agency, U.S . Food, Drug Administration Locations: Danish, U.S, Swiss

☆ Forget keto — Ozempic might finally kill the low-carb diet trend
▼ + stars: | 2024-07-23 | by ( ) www.businessinsider.com time to read: +5 min

Read previewHold the butter — the rise of weight loss medications may be signaling an end to popular high-fat, low-carb diet trends. But interest has begun to wane in recent years, with the number of people on keto diets dropping by 4% in 2023. Some doctors have called keto the worst diet for healthDespite hitting its stride in the mid-2010s, the keto diet has been around for at least a century. Both saturated fat and processed meats are popular in low-carb diet variations like "dirty keto," full of junk food. GLP-1 drugs work for weight loss by mimicking various hormones that naturally occur in the human body and help regulate appetite.

Persons: —, Ozempic, Atkins, they're Organizations: Service, Google, New, Business, Consumer, FDA Locations: carbs, dietitian

☆ Which Weight Loss Drug Should You Choose (if You Get to Choose)?
▼ + stars: | 2024-07-19 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

People with obesity now have a choice between two powerful drugs to help them lose weight. One is semaglutide, sold by Novo Nordisk as Wegovy for obesity treatment and as Ozempic for diabetes. A recent study suggested that people lost more weight taking Mounjaro than they did taking Ozempic, and it may leave you wondering: Which should I take? Is one weight loss drug really better than the other? All of the information available comes from “highly flawed studies,” said Dr. Diana Thiara, medical director of the weight loss clinic at the University of California, San Francisco.

Persons: Eli Lilly, I’m, ”, Diana Thiara Organizations: Novo Nordisk, University of California Locations: San Francisco

☆ Here's why KeyBanc analysts see more than 40% upside for Nvidia stock
▼ + stars: | 2024-07-09 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. KeyBanc raised its price target on the Club chipmaker's stock to $180 per share from $130. New research indicated that tirzepatide, the active ingredient in Lilly's Mounjaro for diabetes and Zepbound for weight loss leads to more weight loss than Novo Nordisk's semaglutide. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Goldman Sachs, Piper Sandler, —, KeyBanc, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Apple, Big Tech, Nvidia, Club, Blackwell, Novo Nordisk's semaglutide

☆ Stocks making the biggest moves midday: Nvidia, Corning, Helen of Troy, UiPath and more
▼ + stars: | 2024-07-09 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Helen of Troy — The housewares stock plummeted nearly 28%, hitting a new 52-week low during the session. The company posted an earnings miss for its first quarter of fiscal 2025 before the bell, earning 99 cents per share, excluding items. Lucid — The electric vehicle company's stock added nearly 1% after rallying about 8% in the previous session. Lucid jumped after the firm said it delivered 2,394 vehicles in the second quarter, marking a 70% year-over-year increase. Tesla — Shares of the electric vehicle company popped more than 4%.

Persons: Blackwell, Helen of Troy —, FactSet, UiPath, Lucid, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Corning, Yun Li, Pia Singh, Sarah Min, Darla Mercado Organizations: Nvidia, UBS, BP — U.S, Novo Nordisk, Novo Nordisk's Ozempic, Sony, Paramount, National Amusements, Skydance Media, Apollo, CNBC Locations: Novo

☆ Mounjaro leads to significantly more weight loss than Ozempic, study suggests
▼ + stars: | 2024-07-08 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

CNN —People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. But 82% of people taking tirzepatide reached this important clinical benchmark, compared with about 67% of those taking semaglutide. Average weight loss was also consistently higher among those taking tirzepatide over time. And by one year, average weight loss was nearly double for those taking tirzepatide — more than 11%, compared with about 6% for those taking semaglutide. According to the new study, individuals with type 2 diabetes had less significant weight loss than those without a diagnosis — but average weight loss was still greater among those taking tirzepatide.

Persons: tirzepatide, Eli Lilly, ”, Dr, Sanjay Gupta, CNN’s Brenda Goodman Organizations: CNN, US Food and Drug Administration, Novo Nordisk, semaglutide, FDA, CNN Health Locations: Truveta

☆ CNBC Daily Open: French far-right advance blocked
▼ + stars: | 2024-07-08 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Far-right advance thwartedFrance's left-wing New Popular Front coalition unexpectedly blocked a far-right advance in the parliamentary run-off vote, securing the largest number of seats but falling short of an absolute majority. Gox bankruptcy estate confirmed that repayments in bitcoin and bitcoin cash had commenced, likely fueling investor concerns of a massive sell-off. However, recent profit-taking and valuation concerns led to a pullback and a rare downgrade from a Wall Street analyst.

Persons: France's, Jan Hatzius, Goldman Sachs, Bitcoin, Emmanuel Papadakis Organizations: CNBC, Popular Front, Rassemblement, Nasdaq, Dow Jones, Federal Reserve, Novo Nordisk, Novo Nordisk's Ozempic, Deutsche Bank, Harvard Medical, Nvidia, Wall Locations: Europe's, U.S, Gox, bitcoin, Novo

☆ Top 5 things to watch in the stock market Friday, including big jobs report
▼ + stars: | 2024-07-05 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

The June employment report on Friday morning came in slightly better than expected with the economy adding 206,000 nonfarm jobs versus 200,000 expected. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. Top things to watch Friday, July 5Stocks were mixed slightly Friday following another record S&P 500 th holiday. The June employment report on Friday morning came in slightly better than expected with the economy adding 206,000 nonfarm jobs versus 200,000 expected.

Persons: Eli Lilly, Jefferies, Jim Cramer's, Jim Cramer, Jim, Constellation Brands Novo Nordisk Eli Lilly Samsung Organizations: Treasury, Constellation Brands, JPMorgan, Novo Nordisk, Samsung Electronics, Jim Cramer's Charitable, CNBC, Constellation Brands Novo Nordisk, Constellation Brands Novo Nordisk Eli Lilly Samsung Electronics

☆ Stocks making the biggest moves premarket: Macy's, Tesla, Novo Nordisk and more
▼ + stars: | 2024-07-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Crypto stocks — Stocks tied to bitcoin price slid after the cryptocurrency dropped 5% to its lowest level since February , with the now defunct Mt. Macy's — Shares of the retailer jumped more than 6% following a Wall Street Journal report that an investor group has hiked its takeout offer. Arkhouse Management and Brigade Capital Management are now offering about $24.80 per share for Macy's, up from $24 previously, the report said. Tesla — The electric vehicle manufacturer popped 2%, marking a continuing comeback after its second-quarter vehicle deliveries number beat analyst estimates earlier this week. Shell — Shares popped 1%.

Persons: Stocks, Energy, CleanSpark, Instructure, Tesla, CNBC's Hakyung Kim, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: Marathon, Francisco Partners, KKR, Reuters, Macy's, Journal, Arkhouse Management, Brigade Capital Management, Novo Nordisk —, Harvard, Novo Nordisk's Ozempic, Deutsche Bank, Shell Locations: Novo, Singapore, Rotterdam

Search resuls for: "semaglutide"

25 mentions found